Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.
April 10, 2017
Alexo Therapeutics Announces Initiation of
Cambridge Healthtech Institute’s 15th Annual Discovery on Target: Targeting Tumor Myeloid Cells
September 28, 2017 – Boston, MA
32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 10, 2017 – National Harbor, MD